Risk for Schizophrenia Increased With ED Visits Involving Hallucinogen Use
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 21, 2024 -- In individuals without a history of psychosis, the risk for developing a schizophrenia spectrum disorder (SSD) is increased for individuals with an emergency department visit involving hallucinogen use, according to a study published online Nov. 13 in JAMA Psychiatry.
Daniel T. Myran, M.D., M.P.H., from the University of Ottawa in Ontario, Canada, and colleagues conducted a population-based, retrospective cohort study involving all individuals aged 14 to 65 years in Ontario with no history of psychosis (SSD- or substance-induced) to examine whether an emergency department visit involving hallucinogen use is associated with an increased risk for developing an SSD. The study included 9,244,292 individuals without a history of psychosis who were followed for a median of 5.1 years.
The researchers found that 0.1 percent of the participants had an incident emergency department visit involving hallucinogen use. Between 2008 and 2012, the annual rates of incident emergency department visits involving hallucinogens were stable and then increased by 86.4 percent between 2013 and 2021 from 3.4 to 6.4 per 100,000 individuals. Compared with the general population, individuals with emergency department visits involving hallucinogens had a greater risk for being diagnosed with an SSD within three years (absolute proportion with SSD at three years: 3.99 versus 0.15 percent; age- and sex-adjusted hazard ratio, 21.32). The increased risk persisted after adjustment for comorbid substance use and mental health conditions (hazard ratio, 3.53). In the fully adjusted model, compared with emergency department visits involving alcohol and cannabis, emergency department visits involving hallucinogens were associated with an increased risk for SSD within three years.
"Given rapid increases in interest in and adult use of hallucinogens and the increase in emergency department visits involving hallucinogens found in this study, ongoing research is needed to clarify the observed association between hallucinogen use and development of SSD," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-22 06:00
Read more
- Supreme Court to Decide on South Carolina's Bid to Cut Funding for Planned Parenthood
- Kids From Poorer Homes May Have Worse Outcomes If MS Strikes
- Dark Chocolate Could Help You Ward Off Type 2 Diabetes
- Women With Severe Maternal Morbidity Less Likely to Have Subsequent Birth
- Small Clinical Benefit Seen for Race-Aware Over Unaware Risk Predictions
- uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions